Please Wait
Applying Filters...
menu
    • menu
    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Ofatumumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 6Gowling WLG (Canada) LLP

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    PharmaCompass
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Gowling WLG (Canada) LLP

    OFATUMUMAB
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Patent Expiration Date : 2023-10-17

    Date Granted : 2019-02-12

    OFATUMUMAB

    Brand Name : ARZERRA

    Patent Number : 2502552

    Filing Date : 2003-10-17

    Strength per Unit : 100 mg / 5 mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : INTRAVENOUS

    Patent Expiration Date : 2023-10-17

    Date Granted : 2019-02-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Gowling WLG (Canada) LLP

    OFATUMUMAB
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Patent Expiration Date : 2023-10-17

    Date Granted : 2019-02-12

    OFATUMUMAB

    Brand Name : ARZERRA

    Patent Number : 2502552

    Filing Date : 2003-10-17

    Strength per Unit : 1000 mg / 50 mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : INTRAVENOUS

    Patent Expiration Date : 2023-10-17

    Date Granted : 2019-02-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Gowling WLG (Canada) LLP

    OFATUMUMAB
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Patent Expiration Date : 2023-10-17

    Date Granted : 2019-02-12

    OFATUMUMAB

    Brand Name : KESIMPTA

    Patent Number : 2502552

    Filing Date : 2003-10-17

    Strength per Unit : 20 mg / 0.4 mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2023-10-17

    Date Granted : 2019-02-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Gowling WLG (Canada) LLP

    OFATUMUMAB
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Patent Expiration Date : 2028-07-03

    Date Granted : 2018-12-04

    OFATUMUMAB

    Brand Name : KESIMPTA

    Patent Number : 2692681

    Filing Date : 2008-07-03

    Strength per Unit : 20 mg / 0.4 mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2028-07-03

    Date Granted : 2018-12-04

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Gowling WLG (Canada) LLP

    OFATUMUMAB
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Patent Expiration Date : 2023-10-17

    Date Granted : 2019-02-12

    OFATUMUMAB

    Brand Name : KESIMPTA

    Patent Number : 2502552

    Filing Date : 2003-10-17

    Strength per Unit : 20 mg / 0.4ml

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2023-10-17

    Date Granted : 2019-02-12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Gowling WLG (Canada) LLP

    OFATUMUMAB
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Gowling WLG (Canada) LLP

    Country
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Patent Expiration Date : 2028-07-03

    Date Granted : 2018-12-04

    OFATUMUMAB

    Brand Name : KESIMPTA

    Patent Number : 2692681

    Filing Date : 2008-07-03

    Strength per Unit : 20 mg / 0.4ml

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2028-07-03

    Date Granted : 2018-12-04

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.